Nasopharyngeal carcinoma (NPC) is known for its high metastatic potential. Here we report the identification of the proteoglycan serglycin (SRGN) as a funcationally significant marker of metastasis in this setting. metastasis-free and disease-free survival. Our findings establish that glycosylated serglycin regulates NPC metastasis via autocrine and paracrine routes, and that it serves as a prognostic indicator of metastasis-free survival and disease-free survival in NPC patients.
Author Manuscript Published OnlineFirst on February 2, 2011; DOI: 10.1158/0008-5472. malignant tumors in southern China and Southeast Asia (1, 2) . NPC has the highest metastasis rate among head and neck cancers (3) (4) (5) , with the majority of the patients having metastases to regional lymph nodes or even distant organs at the time of diagnosis (6) . However, the molecular mechanisms underlying NPC metastasis are poorly understood, and understanding the molecular basis is important for developing novel strategies for prevention and treatment of metastatic NPC. In the present study, high throughput screening identified serglycin correlated with NPC metastasis.
Serglycin is a proteoglycan consisting of a core protein to which negatively charged glycoaminoglycan (GAG) chains of either chondroitin sulfate or heparin are attached (7, 8) . The core protein containing 158 amino acid residues can be divided into 3 domains: a signal peptide domain spanning amino acid residues 1-27 and responsible for secretion; an N-terminal domain consisting of residues 28-76, its function unknown; and a C-terminal domain consisting of residues 77-158 containing a long region of Ser-Gly repeats for GAG attachment (9) . The functions of SG in various cells depend on the type and size of the GAG chains decorating the core protein (8, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .
Serglycin mRNA or protein has been detected in many kinds of cells, e.g., embryonic stem cells, hematopoietic cells, and endothelial cells (11, 14, (20) (21) (22) (23) .
Serglycin is thought to be important for homeostasis of positively charged components (e.g., proteases) in storage granules due to its negatively charged GAG chains (24) (25) (26) (27) (28) . In cytotoxic lymphocytes (CTLs) or natural killer T (NT) cells, a macromolecular complex of granzyme B and perforin complexed with serglycin induces the apoptosis of target cells (29) (30) (31) (32) (33) (34) . Serglycin has been associated with tumorigenesis in acute myeloid leukemia (AML) and myeloma, and it was found to be a selective marker for distinguishing AML from Philadelphia chromosome-negative chronic myeloproliferative disorders. It is constitutively secreted at high levels by multiple myeloma cell lines (35, 36) .
Although the involvement of serglycin in tumor metastasis has been speculated (37), the exact role of serglycin in NPC remains unknown.
The epithelial-mesenchymal transition (EMT), a fundamental process in embryonic development, is involved in the metastasis and progression of tumors (38, 39) . Activation of the EMT program, accompanied by an increase in the mesenchymal marker vimentin and loss of the epithelial marker E-cadherin, endows carcinoma cells with enhanced migratory and invasive properties that facilitate dissemination to permissive niches (39) .
Materials and Methods

Cell culture and cellular growth rate
The human NPC cell line CNE-2 and its clones (S18, S22, and S26, cultured in less than 50 passages), and SUNE-1 and its clone 5-8F were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) at 
In vitro migration and invasion assays
Migration and invasion assays were performed according to the methods described previously with minor modifications (40) . More details were described in the Supplementary Materials and Methods.
Detection of serglycin in conditioned medium
A total of 2 × 10 6 cells were plated in 100-mm culture plates and incubated for 48 h in a regular medium. The medium was then replaced with a serum-free medium (10 ml) and cells were incubated for an additional 24 h.
Ten milliliters of conditioned medium was collected and concentrated to a volume of 200 μl using Amicon Ultra centrifuge filters (10 kDa molecular weight All patients received radiotherapy, with doses of 70-74 Gy to the primary tumor, 60-64 Gy to the involved areas of the neck, and 50 Gy to the uninvolved areas of the neck.
For the patients with late-stage disease (stages III and IV), 2-3 cycles of induction or concurrent platinum-based chemotherapy was given. The patients were followed up regularly with a median follow-up time of 83 months. TMAs were constructed as described previously (41) For IHC staining of serglycin and vimentin, paraffin-embedded tissues were sectioned at 5 µm and immunohistochemical staining was performed as described previously (42) . Briefly, the sections were incubated with a rabbit 
Wound healing assay
Wound healing assays were performed by plating cells in 6-well plates (3 × 10 5 cells/well). After cells were allowed to attach and reach confluence, a scratch was made using a sterile yellow 100 µl pipette tip and detached cells were removed by washing with PBS. Phase contrast images were taken in the same field at the indicated time points. The experiments were performed in triplicate.
Deglycosylation assay
Concentrated conditioned medium containing secreted serglycin protein was treated with an enzymatic Glycoprotein Deglycosylation Kit (EMD Chemicals, Gibbstown, NJ) according to the manufacturer's instructions. 
Genomic expression profiling
The methodology of gene expression profiling is described in the Supplementary Materials and Methods. To identify genes that were differentially expressed between high-and low-metastasis cells/xenografts, the Figure 1A and 1B as heatmaps. The gene expression data for this study have been uploaded to the Gene Expression Omnibus, with the accession number GSE24154.
Statistical methods
Single comparisons were performed using Student's t test, Mann-Whitney test, or Chi-square test (two-tailed; P < 0.05 was considered significant). The Spearman correlation test (2-tailed) was used to calculate the correlation coefficient (r) and P value between the serglycin and vimentin staining scores, or between the serglycin and E-cadherin staining scores. The median of the IHC score value was used as the cutoff value to divide the patients into highand low-SG-expression groups.
The censoring time distribution was estimated by the Kaplan-Meier method and P values were calculated by Log Rank analysis. Cox's regression model was used to assess the contribution of SG in multivariate statistical models of disease-free, distant-metastasis-free, and overall survival. Predictors were judged to be significant at P ≤ 0.05.
Results
Serglycin expression is elevated in NPC cells with higher metastasis potential
We have previously isolated and established cellular clones having different metastatic abilities from the parental NPC cell line, CNE-2 (40).
Among these clones, clone 18 (S18) had the highest metastatic ability, while metastatic ability. To explore the molecular mechanism(s) underlying this important biological behavior, we performed genomic expression profiling of these four cell lines from in vitro cultured cells. In the high-metastasis clone S18, the serglycin gene (SRGN) was the second most highly up-regulated ( Figure 1A ). Considering the potential differences between in vivo and in vitro conditions, xenograft tumors from these four cell lines were generated in nude mice and were collected for gene expression profiling using the same technology. Again, serglycin was the second most up-regulated gene in S18 xenograft ( Figure 1B) .
To confirm the finding from genomic expression profiling, real-time quantitative PCR was performed to quantify the mRNA levels of serglycin among the four lines, with consistent results ( Figure 1C ). Moreover, a high level of serglycin expression was also detected in the high-metastasis clone 5-8F isolated from another parental NPC cell line SUNE-1 with low-metastasis potential (44) ( Figure 1C ). The protein levels of serglycin were also evaluated.
The results showed that S18 and 5-8F cells could secrete serglycin into culture medium, while the other low-metastasis cell lines could not ( Figure 1D ). The specificity of the anti-human serglycin antibody was confirmed and shown in Supplementary Figure 1 . After partial deglycosylation of secreted serglycin, a protein with a lower molecular weight (about 80 kDa) could be detected ( Figure   1E ), confirming the glycosylation of the serglycin protein secreted by high-metastasis cells.
Serglycin is up-regulated in liver metastases from NPC and in highly migratory/invasive NPC cells
To evaluate the clinical relevance of our hypothesis that serglycin regulates NPC metastasis, we collected archival tissues of liver metastases from NPC (n = 16) for comparison with primary NPC tissues (n = 48).
Immunohistochemical (IHC) staining showed that the protein levels of 
serglycin were significantly higher in the liver metastases (Figures 2A and 2B ), implying that serglycin could be important in clinical scenarios.
To confirm that up-regulation of serglycin in highly migratory cells could be repeatedly found, a two-chamber (Boyden chamber) assay was used to isolate highly migratory cells from the parental CNE-2 line. After three sequential passages of screening, highly migratory/invasive cells (CNE-1 M3)
were isolated ( Figure 2C) , and serglycin was found to be highly expressed in these cells ( Figure 2D ).
Lower serglycin secretion suppresses the migration and invasion of NPC cells without influencing growth rate
To examine the causal role of serglycin in motility of NPC cells, we engineered cell lines from S18 that stably expressed either shRNAs targeting serglycin expression (SG KD1 and SG KD2) or a scrambled non-target shRNA.
The suppression of serglycin expression at the mRNA level was confirmed by quantitative real-time PCR ( Figure 3A) . A decrease in secreted serglycin protein was confirmed via immunoblotting ( Figure 3B ). Yet, knocking down serglycin in S18 cells did not alter the growth rate of the cells measured by an MTS assay ( Figure 3C ), implying that serglycin did not have a role in controlling cellular growth. The migration ability of S18 cells was significantly suppressed after the loss of secreted serglycin, as evaluated by a scratch-wound healing assay and a two-chamber assay ( Figures 3D and 3E ).
The invasion ability of S18 cells was also significantly reduced by knocking down serglycin ( Figure 3E ). These results proved that secreted serglycin could promote NPC cell migration and invasion in an autocrine mode.
Secreted SG promotes the motility of low-metastasis NPC cells
To validate the motility-enhancing activity of serglycin in NPC cells, we used lentiviral transduction to generate an S26 cell line stably overexpressing 
serglycin. Overexpression was confirmed by immunoblotting, and secreted serglycin protein was detected in the conditioned medium of overexpressing S26 cells, but not in the conditioned medium of control cells ( Figure 4A ).
Overexpression of serglycin did not alter the growth rate of the cells ( Figure   4B ).
The conditioned medium of S26 cells overexpressing serglycin or the control vector was subjected to 50X concentration (from 10 ml to 200 µl) using 10 K ultrafilters, and concentrated serglycin protein was then confirmed using immunoblotting ( Figure 4C ). The concentrated conditioned medium was used to stimulate migration and invasion by wild-type S26 cells. The numbers of migrated and invaded cells were significantly increased after the stimulation ( Figures 4D and 4E ). These results suggest that serglycin could also promote NPC motility via a paracrine mode, by which secreted serglycin from a rare clone could stimulate the motility of cells unable to secrete serglycin.
Interestingly, prokaryotic recombinant serglcyin without glycosylation modification could not promote migration of CNE-2 and S26 cells (Supplementary Figure 2) , suggesting that the glycosylation of serglycin is critical for promoting cellular motility.
Expression of SG mediates the metastasis rate of NPC in vivo
To determine the effect of serglycin in vivo, we used a spontaneous lymph node metastasis model (40) . As expected, serglycin-knockdown cells showed a significant reduction in metastasis rate, and serglycin-overexpressing cells showed an increased metastasis rate ( Figure 5 ). These results confirmed that serglycin was involved in the control of NPC metastasis in vivo.
Serglycin expression is associated with the epithelial-mesenchymal transition
To explore the relationship of serglycin and EMT, IHC staining of serglycin, To confirm this finding, the protein levels of several EMT markers in four cellular populations were evaluated. A high level of secreted serglycin accompanied elevated levels of mesenchymal markers vimentin, N-cadherin, and fibronectin, and a reduced level of epithelial protein E-cadherin in the high-metastasis S18 cells ( Figure 6D ). The suppression of serglycin resulted in a lower vimentin level, but did not influence the levels of other EMT proteins ( Figure 6E ). All of these data suggest that serglycin is correlated with EMT by mediating the vimentin level.
High-level serglycin expression is an independent, unfavorable prognostic indicator for NPC
Finally, to evaluate the prognostic value of serglycin expression in primary NPC, we performed IHC staining for serglycin in a set of tissue microarrays containing 263 NPC samples with sufficient clinical follow-up information about the patients (Supplementary Table 1 , Figures 7A and 7B) . The patients were divided into low-and high-serglycin expression groups using the median of serglycin staining scores as the cut-off value. The correlations between serglycin expression and clinicopathological characteristics are presented in Supplementary Table 2 .
High serglycin expression was significantly correlated with the occurrence of disease progression or distant metastasis.
Multivariate analyses using Cox's regression model revealed that a high level of serglycin expression was an independent, unfavorable prognostic indicator for disease-free survival and distant-metastasis-free survival (Supplementary Table 3 together, these analyses revealed that high serglycin expression level in NPC significantly correlated with adverse patient outcomes.
Discussion
In the present study, we have identified a metastasis-enhancing glycoprotein, serglycin, by using high-throughput gene expression profiling analyses of CNE-2 clones having low-or high-metastasis potential. There clones possessed high-metastasis ability, with S18 being the most aggressive.
Obviously, if we extract the mRNA from the parental line, the signal from this aggressive clone will be overwhelmed by the majority of low-metastasis populations. However, tumor metastases usually arise from rare clones in the primary tumor (45) . Using the identified culprit clone for comparison can therefore easily reveal the key molecules regulating metastasis.
Among the most up-regulated genes in S18, serglycin is second on the list under both in vitro and in vivo conditions, implying the heavily involvement of this glycoprotein in regulating NPC metastasis. To our knowledge, no published data has directly linked serglycin with tumor metastasis. Our present study has discovered that serglycin is involved in regulating NPC metastasis by promoting the migratory and invasive abilities of NPC cells via autocrine and paracrine modes, with autocrine mechanism seems to be more important. Serglycin expression can also mediate the level of vimentin, which not only is a marker of EMT but also has an important role in regulating cellular migration (46) . Moreover, serglycin is an independent, unfavorable prognostic indicator for distant-metastasis-free survival and disease-free survival in NPC patients.
As shown in Figure 1A and 1B, other genes are also highly expressed in S18 cells, implying that multiple factors could be involved in regulating NPC metastasis. When serglycin expression was knocked down in high-metastasis S18 cells, a 15% reduction in the metastasis rate was achieved, suggesting that targeting multiple factors is a hope for complete suppression of NPC metastasis.
In summary, our study demonstrates that serglycin plays a pivotal role in regulating NPC metastasis by way of enhancing cellular migration, cellular invasiveness, vimentin expression level, and in vivo spread of cancer cells.
Moreover, a high level of serglycin expression can potentially be used to predict shorter disease-free survival and shorter metastasis-free survival of NPC patients. Targeting serglycin could be a novel option for prevention of NPC metastasis. The serglycin protein levels in these lines as determined by western blotting.
(E) The concentrated conditioned medium of S18 cells was deglycosylated at 37 °C for 48 h using an enzymatic deglycosylation kit. After partial deglycosylation, a protein band of 80 kDa was detected by immunoblotting of serglycin, in contrast to the control sample with no enzyme. 
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